Revisiting depot medroxyprogesterone
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20210713Keywords:
Depo-provera, Injection DMPA, LARC, MedroxyprogesteroneAbstract
Background: Injectable contraceptives form an important part of method mix of effective contraceptives used by women worldwide. Depot medroxyprogesterone (DMPA) is a long acting contraceptive which is safe, reversible and does not require any user action to maintain its efficacy.
Methods: This was a prospective questionnaire based study conducted on 84 women who were acceptors of DMPA. The women were interviewed by the same health worker in the local language using a preset questionnaire which included questions regarding the demographic profile, contraceptive choices and positive and negative experiences related to usage of Injection DMPA.
Results: Majority of the women were multiparous, between 25-30 years and were housewives. 19% women had started depo-provera after having one child while 87% started DMPA after their second child. The most common source of information about the contraceptive method was health care worker in 51.1% followed by friends in 30.9% and media in 17.8%. 53 women in the study group chose injection DMPA as it was convenient and safe. The most common side effect seen was amenorrhea followed by irregular bleeding, weight gain and pain abdomen. 91.6% women were satisfied with it and would recommend it to other women.
Conclusions: Addressing the unmet need of family planning requires not only recruiting new clients but also assuring that women continue to use the contraceptive. Method related myths and concerns are an important reason for high discontinuation rates which need to be addressed during counselling sessions.
References
Jacobstein R, Polis CB. Progestin only contraception: injectables and implants. Best Pract Res Clin Obstet Gynecol. 2014;28:795-806.
Khadilkar SS. Short-term use of injectable contraception: an effective strategy for safe motherhood. J Obstet Gynaecol India. 2018;68(2):82-7.
Mehta S, Kale E, Rashid F. Depot medroxyprogesterone: the way forward. Int J Reprod Contracept Obstet Gynecol. 2020;9:2671-2.
Ezegwui H, Ikeako LC, Obiora-Akajor NC. The use of Depot medroxyprogesterone injectable contraceptive in Enugu, Nigeria. Niger J Med. 2012;21(3):266-71.
Abasiattai AM, Udoma EJ, Ukeme E. Depot medroxyprogesterone injectable contraception at the University of Uyo Teaching Hospital, Uyo. Ann Afr Med. 2010;9(2):81-5.
McCall JS, Hett G, Olepo E, Bhattacharya S. Who has a repeat abortion? Identify women at risk of repeated termination of pregnancy: analysis of routinely collected data. J Fam Plann Reprod Health Care. 2016;42(2):133-42.
Skjeldestad FE. The incidence of repeat induced abortion-a prospective cohort study. Acta Obstet Gynecol Scand. 1994;73:706-10.
Fisher WA, Singh SS, Shuper PA, Carey M, Otchet F, MacLean-Brine D, et al. Characteristics of women undergoing repeat induced abortion. CMAJ. 2005;172(5):637-41.
Adeyemi AS, Adekanle DA. Progestogen-only injectable contraceptive: experience of women in Osogbo, southwestern Nigeria. Ann Afr Med. 2012;11(1):27-31.
Ojule JD, Oriji VK, Okongwu C. A five year review of the complications of progestogen only injectable contraceptive at the University of Port-Harcourt Teaching Hospital. Niger J Med. 2010;19(1):87-95.
Balogun OR, Raji HO. Clinical experience with injectable progestogen-only contraceptives at University of Ilorin teaching hospital: A five year review. Niger Postgrad Med J. 2009;16:260-3.
Zerihun MF, Malik T, Ferede YM, Bekele T, Yeshaw Y. Changes in body weight and blood pressure among women using Depo-Provera injection in Northwest Ethiopia. BMC Res Notes. 2019;12(1):512.
Bonny AE, Lange HL, Rogers LK, Gothard DM, Reed MD. A pilot study of depot medroxyprogesterone acetate pharmacokinetics and weight gain in adolescent females. Contraception. 2014;89(5):357-60.
Vickery Z, Madden T, Zhao Q, Secura GM, Allsworth JE, Peipert JF. Weight change at 12 months in users of three progestin-only contraceptive methods. Contraception. 2013;88(4):503-8.
Al-Youzbaki WB. C-reactive protein and lipid profile among depo-medroxyprogesterone acetate injections users. J Ann Coll Med Mosul. 2011;37(2):48-56.
Lopez LM, Ramesh S, Chen M, Edelman A, Otterness C, Trussell J, et al. Progestin-only contraceptives: effects on weight. Cochrane Database Syst Rev. 2016(8):CD008815.
MacLachlan E, Atuyambe LM, Millogo T, Guiella G, Yaro S, Kasasa S, et al. Continuation of subcutaneous or intramuscular injectable contraception when administered by facility-based and community health workers: findings from a prospective cohort study in Burkina Faso and Uganda. Contraception. 2018;98(5):423-9.
Dianat S, Fox E, Ahrens KA, Upadhyay UD, Zlidar VM, Gallo MF, et al. Side effects and health benefits of depot medroxyprogesterone acetate: a systematic review. Obstet Gynecol. 2019;133(2):332-41.
Bigrigg A, Evans M, Gbolade B, Newton J, Pollard L, Szarewski A, et al. Depo provera: position paper. Fam Plann. 2000;26(1):52-3.
Ali MM, Cleland JG, Shah IH, World Health Organization. Causes and consequences of contraceptive discontinuation: evidence from 60 demographic and health surveys. Geneva: World Health Organization; 2012:193.
